241 related articles for article (PubMed ID: 31319147)
1. CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape.
Sun S; Zou H; Li L; Liu Q; Ding N; Zeng L; Li H; Mao S
Int J Pharm; 2019 Sep; 568():118518. PubMed ID: 31319147
[TBL] [Abstract][Full Text] [Related]
2. A novel immunoliposome mediated by CD123 antibody targeting to acute myeloid leukemia cells.
Wang Y; Liu F; Wang Q; Xiang H; Jin H; Li H; Mao S
Int J Pharm; 2017 Aug; 529(1-2):531-542. PubMed ID: 28583331
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia.
Liu FR; Jin H; Wang Y; Chen C; Li M; Mao SJ; Wang Q; Li H
Drug Deliv; 2017 Nov; 24(1):882-890. PubMed ID: 28574300
[TBL] [Abstract][Full Text] [Related]
4. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
[TBL] [Abstract][Full Text] [Related]
5. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
[TBL] [Abstract][Full Text] [Related]
6. [Preparation of CD123 mono-antibody modified tanshinone ⅡA loaded immunoliposome and its in vitro evaluation].
Wang Y; Liu FR; Xiang HL; Qing H; Chen C; Mao SJ; Li H
Zhongguo Zhong Yao Za Zhi; 2017 Jun; 42(11):2085-2091. PubMed ID: 28822152
[TBL] [Abstract][Full Text] [Related]
7. Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile.
Zeng Z; Roobrouck A; Deschamps G; Bonnevaux H; Guerif S; De Brabandere V; Amara C; Dejonckheere E; Virone-Oddos A; Chiron M; Konopleva M; Dullaers M
Blood Adv; 2024 May; 8(9):2059-2073. PubMed ID: 38266153
[TBL] [Abstract][Full Text] [Related]
8. FLT3-ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression.
Soare DS; Radu E; Dumitru I; Popov VM; Bumbea H; Vlădăreanu AM
J Cell Mol Med; 2020 Jul; 24(13):7675-7679. PubMed ID: 32460405
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
Atilla PA; McKenna MK; Watanabe N; Mamonkin M; Brenner MK; Atilla E
Cytotherapy; 2022 Mar; 24(3):282-290. PubMed ID: 34955406
[TBL] [Abstract][Full Text] [Related]
10. Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment.
Guo D; Xu P; Chen D; Wang L; Zhu Y; Zuo Y; Chen B
Int J Nanomedicine; 2020; 15():521-536. PubMed ID: 32021192
[TBL] [Abstract][Full Text] [Related]
11. Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin.
Verdonck LF; Lokhorst HM; Roovers DJ; van Heugten HG
Leuk Res; 1998 Mar; 22(3):249-56. PubMed ID: 9619916
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.
Pizzitola I; Anjos-Afonso F; Rouault-Pierre K; Lassailly F; Tettamanti S; Spinelli O; Biondi A; Biagi E; Bonnet D
Leukemia; 2014 Aug; 28(8):1596-605. PubMed ID: 24504024
[TBL] [Abstract][Full Text] [Related]
13. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.
Ehninger A; Kramer M; Röllig C; Thiede C; Bornhäuser M; von Bonin M; Wermke M; Feldmann A; Bachmann M; Ehninger G; Oelschlägel U
Blood Cancer J; 2014 Jun; 4(6):e218. PubMed ID: 24927407
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia.
Myhren L; Nilssen IM; Nicolas V; Døskeland SO; Barratt G; Herfindal L
Eur J Pharm Biopharm; 2014 Sep; 88(1):186-93. PubMed ID: 24747809
[TBL] [Abstract][Full Text] [Related]
15. Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia.
Qiu L; Zhou G; Cao S
Life Sci; 2020 Feb; 243():117234. PubMed ID: 31887299
[TBL] [Abstract][Full Text] [Related]
16. Co-Delivery of Daunorubicin and Homoharringtonine in Folic Acid Modified-Liposomes for Enhancing Therapeutic Effect on Acute Myeloid Leukemia.
Liu Q; Luo L; Gao X; Zhang D; Feng X; Yang P; Li H; Mao S
J Pharm Sci; 2023 Jan; 112(1):123-131. PubMed ID: 35469834
[TBL] [Abstract][Full Text] [Related]
17. Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia.
Petrov JC; Wada M; Pinz KG; Yan LE; Chen KH; Shuai X; Liu H; Chen X; Leung LH; Salman H; Hagag N; Liu F; Jiang X; Ma Y
Leukemia; 2018 Jun; 32(6):1317-1326. PubMed ID: 29515236
[TBL] [Abstract][Full Text] [Related]
18. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.
Kügler M; Stein C; Kellner C; Mentz K; Saul D; Schwenkert M; Schubert I; Singer H; Oduncu F; Stockmeyer B; Mackensen A; Fey GH
Br J Haematol; 2010 Sep; 150(5):574-86. PubMed ID: 20636437
[TBL] [Abstract][Full Text] [Related]
19. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
20. Antibody-Based Treatment of Acute Myeloid Leukemia.
Garfin PM; Feldman EJ
Curr Hematol Malig Rep; 2016 Dec; 11(6):545-552. PubMed ID: 27734262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
